Skip to main content
Report this ad

See also:

Afrezza: New treatment to replace fast acting insulin injections

There is a new drug that has just been approved for treatment for diabetes type 1 and type 2. It will reduce the need for needles for those patients who currently require fast acting insulin. However, the new drug called Afrezza will not replace the need for slow acting insulin for the diabetics who require this form of medication.

I am one of the diabetics who need both types of insulin. Unfortunately, I will not be able to get the new treatment as it has just been approved by the FDA in the United States and has not made its way to Canada yet.

Afrezza is inhaled and thus will be absorbed quicker than by needle injections. Currently the needle treatments take about an hour for absorption into the bloodstream whereas Afrezza will take approximately 15 to 20 minutes.

“Bruce Bode, MD. the Atlanta diabetes specialist who did a clinical trial funded by MannKind Corporation says that Afrezza is still faster entering the bloodstream than the standard fast acting insulin treatment.

Further more Afrezza leaves the body more quickly than standard fast-acting insulin. “Afrezza is fast in, fast out. It is emulating, in essence, what the pancreas does."

How to use Afrezza

Afrezza comes in a single treatment cartridge containing the drug in the form of a powder. The powder cartridge is placed in a inhaler ready for use.

Comparison between fast acting insulin and Afrezza.

According to the results of 24 month study involving 500 type 1 diabetics, both drugs delivered the same overall results. However, Afrezza had the advantage of not producing the insulin complication for a low blood sugar reading as much as the current fast-acting needle injection treatment. There was also less weight gain which the researcher feels is because the drug does not stay in the body as long.

Now in a second study the researchers found that people with type 2 uncontrolled diabetes had a better chance of blood sugar control using the Afrezza.

Reported side effects

“In the Afrezza clinical trials, the most commonly reported side effects were low blood sugar, cough, and throat pain or irritation, according to the FDA.”

I hope this new drug will soon be allowed into Canada for I have trouble controlling my blood sugar and Afrezza may make that possible.

Note: Computer glitch unable to add photo

Report this ad